Literature DB >> 3764359

Attentional vulnerability indicators, thought disorder, and negative symptoms.

K H Nuechterlein, W S Edell, M Norris, M E Dawson.   

Abstract

Deficits on two continuous performance test versions and the forced-choice span of apprehension task, which are potential vulnerability factors for schizophrenic disorders, were examined in relationship to particular symptoms of schizophrenic disorders, with emphasis on hypothesized relationships to formal thought disorder and negative symptoms. These interrelationships were determined concurrently within a group of 40 schizophrenic patients at an inpatient point. In addition, 32 of these patients were retested at a stabilized outpatient point to address the extent to which continued attentional deficits were associated with specific symptomatology during the hospitalized period. Signal-discrimination deficits on the three tasks were consistently associated with inpatient negative symptoms of schizophrenia as measured by the Anergia factor of the Brief Psychiatric Rating Scale (BPRS), across both the inpatient and outpatient assessments. The outpatient signal-discrimination deficits also showed significant, but less consistent, correlations with inpatient schizophrenic modes of thinking measured by the Rorschach Thought Disorder Index and with formal thought disorder measured by the BPRS Conceptual Disorganization rating. In contrast, no relationship with inpatient hallucinations or delusions was found. Combined with previous findings from high-risk samples, these results are consistent with the view that signal-discrimination deficits in situations demanding high levels of effortful processing are enduring vulnerability factors for schizophrenic negative symptoms and possibly for certain schizophrenic forms of thought disorder.

Entities:  

Mesh:

Year:  1986        PMID: 3764359     DOI: 10.1093/schbul/12.3.408

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  32 in total

Review 1.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

2.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

3.  Psychometric vs. attentional correlates of early onset alcohol and substance abuse.

Authors:  D L Pogge; J Stokes; P D Harvey
Journal:  J Abnorm Child Psychol       Date:  1992-04

4.  Saccadic reaction times in acute and remitted schizophrenics.

Authors:  A Mackert; M Flechtner
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

5.  Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).

Authors:  A McCleery; M F Green; G S Hellemann; L E Baade; J M Gold; R S E Keefe; R S Kern; R I Mesholam-Gately; L J Seidman; K L Subotnik; J Ventura; K H Nuechterlein
Journal:  Psychol Med       Date:  2015-04-28       Impact factor: 7.723

6.  Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.

Authors:  Jee In Kang; Hae-Jeong Park; Se Joo Kim; Kyung Ran Kim; Su Young Lee; Eun Lee; Suk Kyoon An; Jun Soo Kwon; Jong Doo Lee
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

7.  Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo.

Authors:  Garry D Honey; Philip R Corlett; Anthony R Absalom; Michael Lee; Edith Pomarol-Clotet; Graham K Murray; Peter J McKenna; Edward T Bullmore; David K Menon; Paul C Fletcher
Journal:  J Neurosci       Date:  2008-06-18       Impact factor: 6.167

8.  Avoidant personality disorder symptoms in first-degree relatives of schizophrenia patients predict performance on neurocognitive measures: the UCLA family study.

Authors:  D L Fogelson; R A Asarnow; C A Sugar; K L Subotnik; K C Jacobson; M C Neale; K S Kendler; H Kuppinger; K H Nuechterlein
Journal:  Schizophr Res       Date:  2010-01-06       Impact factor: 4.939

9.  Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis.

Authors:  Joseph Ventura; Gerhard S Hellemann; April D Thames; Vanessa Koellner; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2009-07-22       Impact factor: 4.939

Review 10.  Markers of vulnerability in schizophrenia.

Authors:  Maria Ladea; Dan Prelipceanu
Journal:  J Med Life       Date:  2009 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.